Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer

被引：0
|
作者：
Jinno, Hiromitsu
Sato, Tomomi
Takahashi, Maiko
Hayashida, Tetsu
Hirose, Shigemichi
Kitagawa, Yuko
机构：
[1] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan
[2] Keio Univ, Sch Med, Tokyo 160, Japan
[3] Keio Univ, Sch Med, Dept Pathol, Tokyo 160, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 26期
关键词：
D O I：
10.1200/jco.2013.31.26_suppl.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Aya Imai
    Akiko Okamoto
    Asako Hamaoka
    Mari Soushi
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Mariko Goto
    Kei Yamada
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 92 - 97
  • [22] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [23] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [24] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [25] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [26] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [27] Review of the status of neoadjuvant therapy in HER2-positive breast cancer
    Dowling, Gavin P.
    Keelan, Stephen
    Toomey, Sinead
    Daly, Gordon R.
    Hennessy, Bryan T.
    Hill, Arnold D. K.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [28] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [29] Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer
    Sonnenblick, Amir
    Salmon-Divon, Mali
    Salgado, Roberto
    Ponde, Noam
    Loibl, Sibylle
    Denkert, Carsten
    Joensuu, Heikki
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Azaria, Amos
    Loi, Sherene
    Michiels, Stefan
    Sotiriou, Christos
    CANCER RESEARCH, 2020, 80 (04)
  • [30] Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer
    Sonnenblick, Amir
    Salmon-Divon, Mali
    Salgado, Roberto
    Dvash, Efrat
    Ponde, Noam
    Zahavi, Tamar
    Salmon, Asher
    Loibl, Sibylle
    Denkert, Carsten
    Joensuu, Heikki
    Ameye, Lieveke
    Van den Eynden, Gert
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Azaria, Amos
    Loi, Sherene
    Michiels, Stefan
    Richard, Francois
    Sotiriou, Christos
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (01) : 266 - 276
12345